Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

BCBA/BIIB stock hub

BCBA/BIIB has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BCBA/BIIBis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

39.8T

Buenos Aires Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

BCBA/BIIB

In the news

Latest news · BCBA/BIIB

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E13.5

P25 n/aP50 n/aP75 n/a

Trailing P/E21

P25 n/aP50 n/aP75 n/a

ROE7.7

P25 n/aP50 n/aP75 n/a

ROIC10.9

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BCBA/BIIB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

211

Groups with data

Currency

USD

Showing 211 of 211 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	AR
Employees	7,500
Employees Change	-105%
Employees Change Percent	-1.38
Enterprise value	ARS 42.3T
Exchange	Buenos Aires Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	ARS 39.8T
Price	ARS 22,070
Price currency	ARS
Rev Per Employee	1,830,487,232.32x
Sic	2836
Symbol	bcba/BIIB
Website	https://www.biogen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.76%
EV Earnings	22.32x
EV/EBIT	11.19x
EV/EBITDA	8.35x
EV/FCF	12.64x
EV/Sales	3.06x
FCF yield	8.42%
Forward P/E	13.49x
P/B ratio	1.54x
P/E ratio	20.99x
P/S ratio	2.9x
PE Ratio10 Y	16.99x
PE Ratio3 Y	19.86x
PE Ratio5 Y	19.53x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	27.32%
EBITDA Margin	35.38%
FCF margin	24.38%
Gross margin	78.72%
Gross Profit	ARS 10.8T
Gross Profit Growth	2.83%
Gross Profit Growth Q	0.78%
Gross Profit Growth3 Y	-0.4%
Gross Profit Growth5 Y	-6.2%
Net Income	ARS 1.9T
Net Income Growth	-7.26%
Net Income Growth Q	32.85%
Net Income Growth3 Y	-24.05%
Net Income Growth5 Y	-14.55%
Pretax Margin	16.33%
Profit Margin	13.81%
Profit Per Employee	ARS 252.7M
ROA	5.9
Roa5y	6.65
ROCE	10.25
ROE	7.7
Roe5y	13.26
ROIC	10.92
Roic5y	13.81

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	108.81%
Cagr3y	25.36%
Cagr5y	44.62%
EPS Growth	-8.1
EPS Growth Q	31.1
EPS Growth3 Y	-24.42
EPS Growth5 Y	-13.58
FCF Growth	-0.57%
FCF Growth Q	167.46%
FCF Growth3 Y	19.25%
FCF Growth5 Y	-5.2%
OCF Growth	0.36%
OCF Growth Q	148.94%
OCF Growth10 Y	-4.25%
OCF Growth3 Y	15.58%
OCF Growth5 Y	-6.01%
Revenue Growth	1.23x
Revenue Growth Q	1.93x
Revenue Growth3 Y	-0.55x
Revenue Growth5 Y	-4.64x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	ARS 0.35
Assets	ARS 40.7T
Cash	ARS 5.9T
Current Assets	ARS 12.9T
Current Liabilities	ARS 4.2T
Debt	ARS 9.1T
Debt EBITDA	ARS 1.8
Debt Equity	ARS 0.35
Debt FCF	ARS 2.71
Equity	ARS 25.8T
Interest Coverage	9.87
Liabilities	ARS 15T
Long Term Assets	ARS 27.9T
Long Term Liabilities	ARS 10.8T
Net Cash	ARS -2.5T
Net Cash By Market Cap	ARS -6.3
Net Debt EBITDA	ARS 0.52
Net Debt Equity	ARS 0.1
Net Debt FCF	ARS 0.75
Tangible Book Value	ARS 4.3T
Tangible Book Value Per Share	ARS 29,104

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.06
Inventory Turnover	1
Net Working Capital	ARS 2.6T
Quick ratio	2.03
Working Capital	ARS 8.6T
Working Capital Turnover	ARS 3,223

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.01%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	108.7%
200-day SMA	18,563.1
3Y total return	97.02%
50-day SMA	20,957.2
50-day SMA vs 200-day SMA	50over200
5Y total return	532.38%
All Time High	28,500
All Time High Change	-22.56%
All Time High Date	2024-07-04
All Time Low	737
All Time Low Change	2,894.57%
All Time Low Date	2019-04-17
ATR	554.3
Ch YTD	6.41
High	22,390
High52	23,150
High52 Date	2026-02-06
High52ch	-4.67%
Low	21,800
Low52	10,375
Low52 Date	2025-05-08
Low52ch	112.72%
Ma50ch	5.31%
Price vs 200-day SMA	18.89%
RSI	60.22
RSI Monthly	65.5
RSI Weekly	59.57
Sharpe ratio	1.81x
Sortino ratio	2.96
Total Return	-1.01%
Tr YTD	6.41
Tr1m	10.02%
Tr1w	2.75%
Tr3m	-4.21%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	ARS 3.8T
Operating Income Growth	4.02
Operating Income Growth Q	-16.14
Operating Income Growth3 Y	-2.11
Operating Income Growth5 Y	-6.25
Operating margin	27.32

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	147,154,881%
Net Borrowing	-415,261,535,557.3
Shares Insiders	0.2%
Shares Institutions	99.18%
Shares Qo Q	1.16%
Shares Yo Y	1.01%
Short Ratio	3.95

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	ARS 2.9T
Average Volume	895.95x
Bv Per Share	174,577.1
CAPEX	ARS -232B
Ch1m	10.02
Ch1w	2.75
Ch1y	108.7
Ch3m	-4.21
Ch3y	97.02
Ch5y	532.4
Ch6m	26.4
Change	1.19%
Change From Open	0.18
Close	21,810
Days Gap	1.01
Depreciation Amortization	1,120,464,857,308.7
Dollar Volume	39,019,760
Earnings Date	2026-04-29
EBIT	ARS 3.8T
EBITDA	ARS 4.9T
EPS	ARS 12,843
F Score	6
FCF	ARS 3.3T
FCF EV Yield	7.91x
Financing CF	-445,814,470,990
Fiscal Year End	December
Founded	1,978
Goodwill	9,075,471,626,037.9
Graham Number	18392.77938
Graham Upside	-16.66
Income Tax	ARS 346.9B
Investing CF	-2,118,274,956,210
Is Primary Listing	0
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Lynch Fair Value	ARS 5,258
Lynch Upside	-76.18
Ma150	20,008.9
Ma150ch	10.3%
Ma20	21,016
Ma20ch	5.02%
Net CF	1,083,659,346,280
Next Earnings Date	2026-07-29
Open	22,030
P FCF Ratio	11.88
P OCF Ratio	11.11
Position In Range	45.76
Ppne	4,572,492,462,256.4
Price Date	2026-05-08
Price EBITDA	ARS 8.19
Ptbv Ratio	9.26
Relative Volume	1.97x
Revenue	13,728,654,242,380x
SBC By Revenue	2.96x
Share Based Comp	405,888,725,060
Tax By Revenue	2.53x
Tax Rate	15.47%
Tr6m	26.4%
Volume	1,768
Z Score	3.12

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BCBA/BIIB pay a dividend?

Capital-return profile for this ticker.

Performance

BCBA/BIIB stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BCBA/BIIB?

Insider, institutional, and short-interest positioning.

Institutional ownership

+99.2%

Share of float held by funds and institutions

Insider ownership

+0.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BCBA/BIIB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

60.2

Neutral momentum band

Price vs 200-day MA

+18.9%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.81

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BCBA/BIIB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bcba/BIIB stock rating?

bcba/BIIB is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bcba/BIIB analysis?

The full report lives at /stocks/bcba/BIIB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bcba/BIIB?

The latest report frames bcba/BIIB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bcba/BIIB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.